HIPEC Improves Long-Term Outcomes in Stage III Ovarian Cancer

September 25, 2023 9:00 am

The following article is provided by The Clearity Foundation to support women with ovarian cancer and their families. Learn more about The Clearity Foundation and the services we provide directly to women as they make treatment decisions and navigate emotional impacts of their diagnosis.

By Andrea S. Blevins Primeau, PhD, MBA

Adding hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves long-term outcomes in patients with stage III epithelial ovarian cancer, according to updated trial results published in The Lancet Oncology.

These 10-year results from the phase 3 OVHIPEC-1 trial showed that adding HIPEC to surgery provided continued improvement in progression-free survival (PFS) and overall survival (OS).

The study (ClinicalTrials.gov identifier: NCT00426257) included 245 patients, aged 18-76 years, who had stage III epithelial ovarian, fallopian tube, or peritoneal cancer that had not progressed during treatment with at least 3 cycles of neoadjuvant carboplatin and paclitaxel.

The patients were randomly assigned to undergo cytoreductive surgery with HIPEC (n=122) or without it (n=123). Patients in the HIPEC arm received HIPEC (with cisplatin at 100 mg/m²) at the end of surgery. They also received sodium thiosulfate during and after HIPEC. They received an additional 3 cycles of carboplatin (AUC, 5–6 mg/mL per min) and paclitaxel (175 mg/m²) once every 3 weeks as well.

The median follow-up was 10.4 years in the HIPEC arm and 10.1 years in the surgery-alone arm.

The median PFS was 14.3 months in the HIPEC arm and 10.7 months in the surgery-alone arm (hazard ratio [HR], 0.63; 95% CI, 0.48-0.83; P =.0008). The 5-year PFS rate was 12.3% and 6.6%, respectively. The 10-year PFS rate was 10.1% and 6.6%, respectively.

The median OS was 44.9 months in the HIPEC arm and 33.3 months in the surgery-alone arm (HR, 0.70; 95% CI, 0.53-0.92; P =.011). The 5-year OS rate was 36.9% and 19.7%, respectively. The 10-year OS rate was 16.1% and 10.9%, respectively.

Most patients — 82% in the HIPEC arm and 85% in the surgery-alone arm — went on to receive additional anticancer treatment. The most common subsequent therapies were platinum- and non-platinum-based chemotherapy.

“These updated survival results confirm the long-term survival benefit of HIPEC in patients with primary stage III epithelial ovarian cancer undergoing interval cytoreductive surgery,” the researchers concluded.

Disclosures: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.



This article was published by: Cancer Therapy Advisor

Leave a Reply

Your email address will not be published. Required fields are marked *

Return to Blog Home Return to Clearity Foundation Home